MENU
+Compare
GDOC
ETF ticker: NYSE ARCA
AS OF
Jul 3 closing price
Price
$31.85
Change
+$0.06 (+0.19%)
Net Assets
19.9M

GDOC stock forecast, quote, news & analysis

The investment seeks long-term growth of capital... Show more

Category: #Health
GDOC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for GDOC with price predictions
Jul 03, 2025

GDOC in upward trend: price rose above 50-day moving average on May 29, 2025

GDOC moved above its 50-day moving average on May 29, 2025 date and that indicates a change from a downward trend to an upward trend. In of 28 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 01, 2025. You may want to consider a long position or call options on GDOC as a result. In of 66 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for GDOC just turned positive on July 01, 2025. Looking at past instances where GDOC's MACD turned positive, the stock continued to rise in of 35 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for GDOC crossed bullishly above the 50-day moving average on June 04, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 187 cases where GDOC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Unitedhealth Group (NYSE:UNH), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Abbott Laboratories (NYSE:ABT), Intuitive Surgical (NASDAQ:ISRG), Boston Scientific Corp (NYSE:BSX), Align Technology (NASDAQ:ALGN), Exact Sciences Corp (NASDAQ:EXAS).

Industry description

The investment seeks long-term growth of capital. The fund invests, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes (measured at the time of purchase) in equity investments in U.S. and non‑U.S. health care companies. The adviser generally intends to invest in companies that the adviser believes are aligned with key themes associated with innovation in health care, which include, but are not limited to, genomics, precision medicine, technology-enabled procedures, and digital healthcare. The fund is non-diversified.

Market Cap

The average market capitalization across the Goldman Sachs Future Health Care Eq ETF ETF is 76.82B. The market cap for tickers in the group ranges from 2.05B to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is CGON at 2.05B.

High and low price notable news

The average weekly price growth across all stocks in the Goldman Sachs Future Health Care Eq ETF ETF was 1%. For the same ETF, the average monthly price growth was 2%, and the average quarterly price growth was -1%. APGE experienced the highest price growth at 8%, while IRTC experienced the biggest fall at -7%.

Volume

The average weekly volume growth across all stocks in the Goldman Sachs Future Health Care Eq ETF ETF was -35%. For the same stocks of the ETF, the average monthly volume growth was -52% and the average quarterly volume growth was -3%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 74
Price Growth Rating: 53
SMR Rating: 63
Profit Risk Rating: 70
Seasonality Score: 10 (-100 ... +100)
View a ticker or compare two or three
GDOC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
Goldman Sachs ETF Trust200 West StreetNew York
Phone
N/A
Web
N/A